Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032

Neoplasia

Volumn 13, Issue 12, 2011, Pages 1132-1142

  Vergani, Elisabetta ^a   Vallacchi, Viviana ^a   Frigerio, Simona ^a   Deho, Paola ^a   Mondellini, Piera ^a   Perego, Paola ^a   Cassinelli, Giuliana ^a   Lanzi, Cinzia ^a   Testi, Maria Adele ^a   Rivoltini, Licia ^a   Bongarzone, Italia ^a   Rodolfo, Monica ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; VEMURAFENIB;

ARTICLE; BETA CATENIN GENE; BRAF GENE; CANCER RESISTANCE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CYCLIN D1 GENE; ENZYME ACTIVATION; ENZYME INACTIVATION; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; MET GENE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR GENE; MIGRATION INHIBITION; MITOSIS INHIBITION; MUTATOR GENE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE GENE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

EID: 84855460594     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111102     Document Type: Article

References (51)

1. Dhomen N and Marais R (2007). New insight into BRAF mutations in cancer. Curr Opin Genet Dev 17, 31-39.
2. Zheng B, Jeong JH, Asara JM, Yuan YY, Granter SR, Chin L, and Cantley LC (2009). Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell 33, 237-247.
3. Romano E, Schwartz GK, Chapman PB, Wolchock JD, and Carvajal RD (2011). Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 12, 913-922.
4. Sala E, Mologni L, Truffa S, Gaetano C, Bollag GE, and Gambacorti-Passerini C (2008). BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 6, 751-759.
5. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, et al. (2010). RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 70, 5518-5527.
6. Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, et al. (2010). The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci USA 107, 14903-14908.
7. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, et al. (2010). PLX4032, a potent inhibitor of the B-raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell Melanoma Res 23, 820-827.
8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363, 809-819.
9. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507-2516.
11. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al. (2010). Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977.
12. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972.
13. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683-695.
14. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29, 3085-3096.
15. Daniotti M, Oggionni M, Ranzani T, Vallacchi V, Campi V, Di Stasi D, Torre GD, Perrone F, Luoni C, Suardi S, et al. (2004). BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene 23, 5968-5977.
16. Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, Laccabue D, Supino R, Belluco S, Favini E, et al. (2006). Inhibition of c-met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 5, 2388-2397.
17. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L, and Khuri FR (2002). Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8, 1178-1184.
18. Gorla L, Cantu M, Micciche F, Patelli C, Mondellini P, Pierotti MA, and Bongarzone I (2006). RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism. Cell Signal 18, 2272-2282.
19. Caccia D, Micciche F, Cassinelli G, Mondellini P, Casalini P, and Bongarzone I (2010). Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Mol Cancer 9, 278.
20. Zanchi C, Zuco V, Lanzi C, Supino R, and Zunino F (2005). Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer Res 65, 2364-2372.
21. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68, 4853-4861.
22. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, et al. (2001). A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61, 6034-6037.
23. Wei X, Walia V, Lin JC, Teer JK, Prickett TD, Gartner J, Davis S, Stemke-Hale K, Davies MA, NISC Comparative Sequencing Program, et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 43, 442-446.
24. Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD, Varela I, Lin ML, Ordonez GR, Bignell GR, et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
25. Smalley KS, Lioni M, Dalla Palma M, Xiao M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, et al. (2008). Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAFV600E-mutated melanomas. Mol Cancer Ther 7, 2876-2883.
26. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106, 20411-20416.
27. Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, et al. (2010). Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci Transl Med 2, 35ra41.
28. Halaban R, Zhang W, Bacchiocchi A, Cheng E, Parisi F, Ariyan S, Krauthammer M, McCusker JP, Kluger Y, and Sznol M (2010). PLX4032, a selective BRAF (V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 23, 190-200.
29. Sondergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, et al. (2010). Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med 8, 39.
30. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, et al. (2010). Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637-649.
31. Willmore-Payne C, Holden JA, Hirschowitz S, and Layfield LJ (2006). BRAF and c-kit gene copy number in mutation-positive malignant melanoma. Hum Pathol 37, 520-527.
32. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, and Engelman JA (2010). BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3, ra84.
33. Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 71, 2750-2760.
34. Chen YJ, Huang WC, Wei YL, Hsu SC, Yuan P, Lin HY, Wistuba II, Lee JJ, Yen CJ, Su WC, et al. (2011). Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One 6, e21428.
35. Lemos C, Kathmann I, Giovannetti E, Calhau C, Jansen G, and Peters GJ (2009). Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer 100, 1120-1127.
36. Moore SR, Persons DL, Sosman JA, Bobadilla D, Bedell V, Smith DD, Wolman SR, Tuthill RJ, Moon J, Sondak VK, et al. (2008). Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a Southwest Oncology Group study (S9431). Clin Cancer Res 14, 2927-2935.
37. Utikal J, Udart M, Leiter U, Peter RU, and Krahn G (2005). Additional cyclin D(1) gene copies associated with chromosome 11 aberrations in cutaneous malignant melanoma. Int J Oncol 26, 597-605.
38. Takata M, Suzuki T, Ansai S, Kimura T, Shirasaki F, Hatta N, and Saida T (2005). Genome profiling of melanocytic tumors using multiplex ligationdependent probe amplification (MLPA): its usefulness as an adjunctive diagnostic tool for melanocytic tumors. J Dermatol Sci 40, 51-57.
39. Puri N, Ahmed S, Janamanchi V, Tretiakova M, Zumba O, Krausz T, Jagadeeswaran R, and Salgia R (2007). c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13, 2246-2253.
40. Kenessey I, Keszthelyi M, Kramer Z, Berta J, Adam A, Dobos J, Mildner M, Flachner B, Cseh S, Barna G, et al. (2010). Inhibition of c-met with the specific small molecule tyrosine kinase inhibitor SU11274 decreases growth and metastasis formation of experimental human melanoma. Curr Cancer Drug Targets 10, 332-342.
41. Tang MK, Zhou HY, Yam JW, and Wong AS (2010). c-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 12, 128-138.
42. Seidl H, Weger W, Wolf P, Kerl H, and Schaider H (2008). Lack of oncogenic mutations in the c-met catalytic tyrosine kinase domain in acral lentiginous melanoma. Int J Dermatol 47, 1327-1329.
43. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, and Herlyn M (2001). Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 20, 8125-8135.
44. Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, and Grimm EA (in press). Association of activated c-met with NRAS-mutated human melanomas: a possible avenue for targeting. Int J Cancer.
45. Beuret L, Flori E, Denoyelle C, Bille K, Busca R, Picardo M, Bertolotto C, and Ballotti R (2007). Up-regulation of MET expression by α-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis. J Biol Chem 282, 14140-14147.
46. Eustace AJ, Crown J, Clynes M, and O'Donovan N (2008). Preclinical evaluation of dasatinib, a potent src kinase inhibitor, in melanoma cell lines. J Transl Med 6, 53.
47. Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, and Kluger HM (2011). In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell Melanoma Res 24, 386-389.
48. Genersch E, Hayess K, Neuenfeld Y, and Haller H (2000). Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of ras-dependent and-independent pathways. J Cell Sci 23(113 pt), 4319-4330.
49. Sumimoto H, Miyagishi M, Miyoshi H, Yamagata S, Shimizu A, Taira K, and Kawakami Y (2004). Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene 23, 6031-6039.
50. Stella GM, Benvenuti S, and Comoglio PM (2010). Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs 19, 1381-1394.
51. Sen B and Johnson FM (2011). Regulation of SRC family kinases in human cancers. J Signal Transduct 2011, 865819.